News for Exicure, Inc. (XCUR)

\n Exicure, Inc. (XCUR) completes patient enrollment for Phase 2 trial of GPC-100 in multiple myeloma. Topline results from the study expected in the secon

We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks. The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty losses, […]

Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinic

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (”œExicure”) is p

On March 18, 2025, Exicure Inc (XCUR) released its 8-K filing detailing its financial results for the fiscal year 2024. Exicure Inc, a biotechnology company, fo

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid

Exicure reports FY GAAP EPS of -$4.75 with $0.5M revenue. Liquidity concerns arise as additional financing is needed for operations.

Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses The

New York-based Y-mAbs Therapeutics, Inc. (YMAB) is down over 26 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Diginex Limited is up over 107 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Massachusetts-based Immuneering Corporation (IMRX), a clinical-stage oncology company is up over 113 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Exicure (XCUR) partners with GPCR Therapeutics to acquire GPCR USA, transfer technology, and collaborate on drug development pipelines.

Please replace the release dated December 20, 2024 with the following corrected version due to multiple revisions. The updated release reads: EXICURE, INC.

Exicure, Inc. (Nasdaq: XCUR, ”œthe Company”, ”œExicure”), today announced that in connection with the change of control transaction approved by the stock

Israel-based software business My Size, Inc. (MYSZ) is up over 372 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Switzerland-based chipmaker SEALSQ Corp (LAES) is up over 83 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Switzerland-based chipmaker SEALSQ Corp (LAES) is up over 83 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.